Puma Biotechnology, Inc.
PBYI
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabinā¦ read more
Healthcare
Biotechnology
13 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$5.63
Price+0.18%
$0.01
1Y
Price
Market Cap
$283.702m
Small
Price/Earnings 3y Avg5y Avg
7.6x
Premium
Premium
Financials Overview
Key metrics over the past few years+24.7%
EBITDA Margin+16.2%
Net Profit Margin+17.7%
Free Cash Flow MarginRevenue
$211.995m
-8.0%
1y CAGR-2.3%
3y CAGR-4.2%
5y CAGREarnings
$36.978m
+22.1%
1y CAGR+359837.5%
3y CAGR+269903.1%
5y CAGREPS
$0.74
+19.4%
1y CAGR+735.7%
3y CAGR+577.5%
5y CAGRBook Value
$115.268m
$202.862m
Assets$87.594m
Liabilities$41.052m
DebtDebt to Assets
20.2%
0.8x
Debt to EBITDAFree Cash Flow
$42.867m
+10.3%
1y CAGR+114.6%
3y CAGR+33.3%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company